Jammu, April 28 (IANS) The All-India Institute of Medical Sciences (AIIMS) Jammu on Monday launched the Centre for Advanced Genomics and Precision Medicine to boost affordable, precision-driven cancer care with advanced Next Generation Sequencing (NGS) technology.
The Centre, developed in collaboration with oncology company 4baseCare, is equipped with the Illumina NextSeq 2000 sequencing machine, offering comprehensive genomic profiling for cancer patients.
The powerful technology enables clinicians to design highly personalised, targeted treatment plans tailored to each patient’s unique molecular profile. AIIMS Jammu announced its collaboration with 4baseCare in January.
“For every patient we treat, we are treating a mother, a father, a sister, or a brother. This partnership is our promise to every family who walks through our doors that we will do everything in our power to bring them the care they deserve,” Prof (Dr) Shakti Kumar Gupta, Executive Director and CEO, AIIMS Jammu.
“By integrating cutting-edge genomic data with AI-powered diagnostics, the Centre is poised to significantly improve early disease detection, refine therapy choices, and minimise ineffective treatments — ultimately enhancing both patient outcomes and quality of life,” said Dr. Sudharshan Elangovan, Vice President – Global Operations at 4baseCare.
Traditionally, access to such advanced genomic testing has been prohibitively expensive for many patients. However, with this initiative, high-quality NGS-based tests will now be made available at affordable costs, paving the way for greater inclusivity in precision oncology across India.
Further solidifying its role as a national referral hub, the Centre will accept samples from patients and healthcare providers across the country, ensuring that cutting-edge molecular diagnostics are accessible, regardless of geographical barriers.
The Centre will focus on targeted, biomarker-driven therapies, enabling personalised treatment plans to improve outcomes and quality of life of cancer patients.
Using genomics the facility also aims to tackle rare diseases. And to boost healthier pregnancies, the centre will integrate cutting-edge genetic technologies such as Non-Invasive Prenatal Testing (NIPT), Preimplantation Genetic Screening (PGS), and Preimplantation Genetic Diagnosis (PGD).
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
